Drug Trial Radar · NCT07911124
Ticagrelor for Inflammation and Cardiovascular Risk in Patients With Chronic Kidney Disease
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
230
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Dec 2030
Study completion Jul 2031
Sponsor
- Lead sponsor
- University of ArkansasAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- First posted
- Nov 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if treatment with ticagrelor tablets can decrease inflammation in patients with Chronic Kidney Disease (CKD). Inflammation is thought to contribute to the risk of heart disease which is the leading cause of death in patients with CKD. Decreasing inflammation may decrease the risk of heart disease. The main questions it aims to answer are: * Why are patients with CKD at increased risk for heart disease and how to reduce that risk in the future. * If there could be new treatment options for managing inflammation in blood of patients with CKD. Researchers will compare Ticagrelor to a Placebo (a look-alike substance that contains no drug) to see if ticagrelor decreases inflammation in adult patients with CKD. A comparator (control) group not receiving the drug/placebo will consist of adults without CKD. Participants with CKD will: * Take ticagrelor 90 mg or placebo orally twice daily for 42 days * Visit the clinic once every 2 weeks for checkups, tests, and bloodwork * Participation will last approximately 12 weeks Participants without CKD (control group) will visit the clinic twice (7 weeks apart) to provide information and bloodwork. Participation will last approximately 7 weeks with additional optional visits.
Conditions
- Chronic Kidney Disease (CKD)
Interventions
Ticagrelor: an oral, direct-acting, reversibly binding P2Y12 receptor antagonistDrug
Ticagrelor 90 mg orally twice daily for 42 days
PlaceboDrug
Placebo orally twice daily for 42 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Aim 1: post-treatment IL-1β valueTime frame: from baseline (day 0) to post-treatment (day 42)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Arkansas for Medical Sciences
Little Rock, Arkansas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.